Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Zanubrutinib, Liso-Cel Data Highlight the Evolving Treatment Landscape in CLL

June 12th 2023

Luke J. Mountjoy, DO, discusses the implications of the SEQUOIA and the ALPINE trial, the importance of coming up with feasible and effective treatment options for patients with 17p deletions and TP53 mutations, and the investigation of liso-cel in patients with relapsed/refractory CLL.

Phase 3 CLL12 Data Support Watch-and-Wait Approach in Early-Stage CLL

June 11th 2023

Ibrutinib did not prolong survival vs placebo and is linked with increased susceptibility to bleeding in patients with asymptomatic early-stage chronic lymphocytic leukemia, suggesting that a watch-and-wait approach should continue as the standard for this population.

Venetoclax Plus Rituximab Provides Long-Term Survival Benefit in Relapsed/Refractory CLL

June 11th 2023

Treatment with fixed-duration venetoclax plus rituximab continued to show superior survival benefit vs bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, according to 7-year follow up data from the phase 3 MURANO trial.

Acalabrutinib Has Tolerable Safety Profile in Older, Frail CLL Population

June 9th 2023

Acalabrutinib is safe in patients with chronic lymphocytic leukemia who are at least 80 years of age and/or frail.

Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

June 8th 2023

Acalabrutinib and zanubrutinib demonstrated similar investigator-assessed progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia.

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL

May 27th 2023

The combination of venetoclax and obinutuzumab with or without ibrutinib generated higher rates of undetectable minimal residual disease (MRD) and progression-free survival vs chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.

METTL3 Controls Splicing Factor Abundance and Aids Progression in CLL

May 24th 2023

Yiming Wu, PhD, discusses the rationale for studying splicing defects in patients with chronic lymphocytic leukemia without spliceosome mutations, shared key findings from this study, and emphasized how these findings support further research with METTL3 in chronic lymphocytic leukemia and other hematologic malignancies with RNA splicing dysregulation.

China Approves Zanubrutinib in Previously Untreated CLL/SLL and Waldenström Macroglobulinemia

May 8th 2023

China’s National Medical Products Administration has approved 2 supplemental new drug applications of zanubrutinib for use in treatment-naïve adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström macroglobulinemia.

Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL Progression

April 26th 2023

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

Fixed-Duration Ibrutinib Plus Venetoclax Earns Approval in Canada for Previously Untreated CLL

March 28th 2023

Canada Health has approved the fixed-duration, all-oral combination of ibrutinib and venetoclax for the frontline treatment of adult patients with chronic lymphocytic leukemia, including those with 17p deletion.

Unmet Needs and Future Directions in Care in CLL

March 8th 2023

Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.

Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

March 8th 2023

An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.

Dr. Mato on the Potential Use of Noncovalent BTK Inhibitors in CLL

March 2nd 2023

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia

March 1st 2023

Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.

Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia

March 1st 2023

Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.

Davids Highlights Mounting Treatment Options in CLL

February 25th 2023

Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.

Acalabrutinib Tablet Formulation Approved in Europe for Chronic Lymphocytic Leukemia

February 22nd 2023

The European Commission has approved the tablet formulation of acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia.

Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

February 22nd 2023

Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.

Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL

February 22nd 2023

Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.

Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy

February 15th 2023

Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.